NUREXONE BIOLOGIC INC (NRX.CA) Stock Cash Flow
TSX-V:NRX - CA67059R1091 - Common Stock
0.81 CAD
-0.02 (-2.41%)
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -5.80M | -5.04M | -3.64M | -8.17M | -130.00K | |||
| Depreciation Amortization | 113.00K | 85.00K | 33.00K | 6.00K | N/A | |||
| Change In Working Capital | -5.00K | -923.00K | 4.00K | 237.00K | 60.00K | |||
| Other non cash items | 1.28M | 993.00K | 661.00K | 4.08M | N/A | |||
| OPERATING CASH FLOW | -4.41M | -4.89M | -2.94M | -3.85M | -80.00K | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -440.00K | -649.00K | -120.00K | -52.00K | N/A | |||
| Other Investing Activity | N/A | -9.00K | 23.00K | -37.00K | -1.69M | |||
| INVESTING CASH FLOW | -449.00K | -658.00K | -97.00K | -89.00K | -1.69M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -25.00K | -30.00K | -28.00K | 96.00K | N/A | |||
| Stock Issued/Repurchased | 2.34M | 5.84M | 1.06M | 1.45M | N/A | |||
| Other Financing Activity | N/A | 71.00K | 95.00K | 2.75M | 1.76M | |||
| FINANCING CASH FLOW | 2.39M | 5.88M | 1.13M | 4.29M | 1.76M | |||
| Exchange Rate Effect | -199.00K | -173.00K | -16.00K | -109.00K | N/A | |||
| CHANGE IN CASH | -2.67M | 159.00K | -1.92M | 249.00K | -10.00K | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -4.41M | -4.89M | -2.94M | -3.85M | -80.00K | |||
| Capital Expenditure | -440.00K | -649.00K | -120.00K | -52.00K | N/A | |||
| FREE CASH FLOW | -4.85M | -5.54M | -3.06M | -3.90M | -80.00K | |||
All data in USD